ATAI
ATAI Life Sciences BVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.40B
P/E Ratio
—
EPS
$-2.84
Beta
1.60
52W High
$6.75
52W Low
$2.00
50-Day MA
$4.16
200-Day MA
$4.30
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About ATAI Life Sciences BV
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
Fundamentals
| Revenue (TTM) | $3.49M |
| Gross Profit (TTM) | $-54.61M |
| EBITDA | $-121.90M |
| Operating Margin | -3239.00% |
| Return on Equity | -378.00% |
| Return on Assets | -33.30% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.56 |
| Price-to-Book | 7.04 |
| Price-to-Sales (TTM) | 401.10 |
| EV/Revenue | 335.51 |
| EV/EBITDA | 0.27 |
| Quarterly Earnings Growth (YoY) | -96.80% |
| Quarterly Revenue Growth (YoY) | -38.70% |
| Shares Outstanding | $368.17M |
| Float | $303.69M |
| % Insiders | 2.35% |
| % Institutions | 43.51% |
Historical Volatility
HV 10-Day
85.24%
HV 20-Day
69.93%
HV 30-Day
63.37%
HV 60-Day
68.36%
HV Rank
21.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($14.00 target)
2
Strong Buy12
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026